Introduction {#s1}
============

JAK/STAT activating signals are critical regulators of many biological processes in animals. Originally described mainly in immune contexts, it has increasingly become clear that JAK/STAT signalling is also central to metabolic regulation in many tissues ([@bib15]; [@bib35]). One common consequence of activation of JAK/STAT pathways in inflammatory contexts is insulin resistance in target tissues, including muscle ([@bib20]; [@bib23]). However, it is difficult to describe a general metabolic interaction between JAK/STAT and insulin signalling in mammals, due to different effects at different developmental stages, differences between acute and chronic actions, and the large number of JAKs and STATs present in mammalian genomes ([@bib15]; [@bib24]; [@bib27]; [@bib34]).

The fruit fly *Drosophila melanogaster* has a single, well-conserved JAK/STAT signalling pathway. The *unpaired (upd)* genes *upd1-3* encode the three known ligands for this pathway; they signal by binding to a single common GP130-like receptor, encoded by *domeless* (*dome*) ([@bib1]; [@bib10]; [@bib13]). Upon ligand binding, the single JAK tyrosine kinase in *Drosophila*, encoded by *hopscotch* (*hop*), is activated; Hop then activates the single known STAT, STAT92E, which functions as a homodimer ([@bib7]; [@bib13]; [@bib17]; [@bib37]). This signalling pathway plays a wide variety of functions, including segmentation of the early embryo, regulation of hematopoiesis, maintenance and differentiation of stem cells in the gut, and immune modulation ([@bib2]; [@bib26]). Importantly, several recent studies indicate roles for *upd* cytokines in metabolic regulation; for example, *upd*s are important nutrient-responsive signals in the adult fly ([@bib6]; [@bib29]; [@bib36]; [@bib39]).

Here, we identify a physiological requirement for Dome signalling in adult muscle. We observe that adult muscles show significant JAK/STAT signalling activity in the absence of obvious immune challenge. Plasmatocytes are a source of this signal. Inactivation of *dome* on adult muscles significantly reduces lifespan and causes muscular pathology and physiological dysfunction; these result from remarkably strong AKT hyperactivation and consequent dysregulation of metabolism. We thus describe a new role for JAK/STAT signalling in adult *Drosophila* muscle with critical importance in healthy metabolic regulation.

Results {#s2}
=======

*Dome* is required in adult muscle {#s2-1}
----------------------------------

To find physiological functions of JAK/STAT signalling in the adult fly, we identified tissues with basal JAK/STAT pathway activity using a STAT-responsive GFP reporter (*10xSTAT92E-GFP*) ([@bib4]). The strongest reporter activity we observed was in legs and thorax. We examined flies also carrying a muscle myosin heavy chain RFP reporter (*MHC-RFP*) and observed co-localization of GFP and RFP expression in the muscles of the legs, thorax and body wall ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We observed strong, somewhat heterogeneous reporter expression in all the muscles of the thorax and the legs, with strong expression in various leg and jump muscles and apparently weaker expression throughout the body wall muscles and indirect flight muscles ([Figure 1A](#fig1){ref-type="fig"}). *dome* encodes the only known *Drosophila* STAT-activating receptor. To investigate the physiological role of this signal, we expressed *dome^Δ^*, a dominant-negative version of Dome lacking the intracellular signalling domain, with a temperature-inducible muscle specific driver line (*w;tubulin-Gal80^ts^;24B-Gal4*) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) ([@bib10]). Controls (*24B-Gal80^ts^/+*) and experimental flies (*24B-Gal80^ts^ \> dome^∆^*) were raised at 18°C until eclosion to permit Dome activity during development. Flies were then shifted to 29°C to inhibit Dome activity and their lifespan was monitored. Flies with Dome signalling inhibited in adult muscles were short-lived ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). This effect was also observed, more weakly, in flies kept at 25°C ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Upd-JAK-STAT signalling is important to maintain gut integrity, and defects in gut integrity often precede death in *Drosophil*a; however, our flies did not exhibit loss of gut integrity ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) ([@bib18]; [@bib30]). To determine whether Dome inhibition caused meaningful physiological dysfunction, we assayed climbing activity in *24B-Gal80^ts^/+* control flies and *24B-Gal80^ts^ \> dome^∆^* flies. *24B-Gal80^ts^ \> dome^∆^* flies showed significantly impaired climbing compared to controls ([Figure 1C](#fig1){ref-type="fig"}). Adult muscle-specific expression of *dome^Δ^* with a second Gal4 line (*w;tub-Gal80^ts^;Mef2-Gal4*) gave a similar reduction in lifespan and decline in climbing activity, confirming that the defect resulted from a requirement for Dome activity in muscle ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

![Dome inhibition in adult muscle reduces lifespan, disrupts homeostasis, and causes AKT hyperactivation.\
(**A**) STAT activity in different muscles in 10xSTAT92E-GFP reporter fly. One fly out of 5 shown. Upper panel: lateral view, Scale bar = 500 µm. Lower panels: dorsal thorax (left); dorsal abdomen (middle); tibia (right), Scale bar = 100 µm. (**B**) Lifespan of *24B-Gal80^ts^/+* and *24B-Gal80^ts^ \> dome^∆^* at 29°C. Log-Rank test: χ^2^ = 166, \*\*\*p\<0.0001; Wilcoxon test: χ^2^ = 157.7, \*\*\*p\<0.0001. (**C**) Negative geotaxis assay of 14-day-old *24B-Gal80^ts^/+* and *24B-Gal80^ts^ \> dome^∆^* flies. Points represent mean height climbed in individual vials (\~20 flies/vial), pooled from three independent experiments. Unpaired T-test: \*\*p=0.0033. (**D**) Muscle (Phalloidin) and neutral lipid (LipidTox) of thorax samples from 14-day-old *24B-Gal80^ts^/+* and *24B-Gal80^ts^ \> dome^∆^* flies. One representative fly per genotype is shown of six analysed. Scale bar = 50 µm. (**E**) Thin layer chromatography (TLC) of triglycerides in 7-day-old *24B-Gal80^ts^/+* and *24B-Gal80^ts^ \> dome^∆^* flies, n = 3--4 per genotype. One experiment of two is shown. Unpaired T-Test: \*\*\*p\<0.0001. (**F**) Glucose and trehalose (left) and glycogen (right) in 7-day-old *24B-Gal80^ts^/+* and *24B-Gal80^ts^ \> dome^∆^* flies, pooled from two independent experiments. Unpaired T-Test (Glucose +Trehalose): \*\*\*p*\<0.0001* and unpaired T-Test (Glycogen): \*\*\*p\<0.0001. (**G**) CO~2~ produced, O~2~ consumed, and RQ of 7-day-old *24B-Gal80^ts^/+* and *24B-Gal80^ts^ \> dome^∆^* flies. Box plots show data from one representative experiment of three, with data collected from a 24 hr measurement pooled from 3 to 4 tubes per genotype with 10 flies/tube. P values from Mann-Whitney test. (**H--L**) Western blots of leg protein from 14-day-old *24B-Gal80^ts^/+* and *24B-Gal80^ts^ \> dome^∆^* flies. (**H**) Phospho-AKT (S505). One experiment of four is shown. Unpaired T-Test: \*\*\*p\<0.0001. (**I**) Total AKT. One experiment of two is shown. Unpaired T-Test: \*\*p=0.0017. (**J**) Phospho-p70 S6K (T398). One experiment of two is shown. Unpaired T-Test: ns p=0.0539. (**K**) Phospho-AMPKα (T173). One experiment of three is shown. Unpaired T-Test: ns p=0.1024. (**L**) Phospho-ERK (T202/Y204). One experiment of three is shown. Unpaired T-Test: ns p=0.0826.](elife-51595-fig1){#fig1}

Impaired muscle function is sometimes accompanied by lipid accumulation ([@bib5]). Therefore, we stained thorax muscles with the neutral lipid dye LipidTox. In 14 day old flies, we detected numerous small neutral lipid inclusions in several muscles, including the large jump muscle (TTM), of *24B-Gal80^ts^ \> dome^∆^* flies ([Figure 1D](#fig1){ref-type="fig"}).

Muscle *dome* activity is required for normal systemic homeostasis {#s2-2}
------------------------------------------------------------------

Having observed lipid inclusions in adult muscles, we analysed the systemic metabolic state of *24B-Gal80^ts^ \> dome^∆^* flies. We observed significant reductions in total triglyceride, glycogen and free sugar (glucose + trehalose) in these animals ([Figure 1E,F](#fig1){ref-type="fig"}).

Reduced free sugar could result from increased cellular sugar uptake. Increased uptake of sugars by peripheral tissues should be reflected in increased metabolic stores or metabolic rate. Since metabolic stores were decreased in our flies, we tested metabolic rate by measuring respiration. CO~2~ production and O~2~ consumption were both significantly increased in *24B-Gal80^ts^ \> dome^∆^* flies, indicating an overall increase in metabolic rate ([Figure 1G](#fig1){ref-type="fig"}). *dome* acts via *hop* to regulate AKT activity with little effect on other nutrient signalling pathways.

The observed metabolic changes imply differences in activity of nutrient-regulated signalling pathways in *24B-Gal80^ts^ \> dome^∆^* flies. Several signalling pathways respond to nutrients, or their absence, to coordinate energy consumption and storage ([@bib9]; [@bib21]; [@bib32]). Of these, insulin signalling via AKT is the primary driver of sugar uptake by peripheral tissues.

We examined the activity of these signalling mechanisms in legs (a tissue source strongly enriched in muscle) from *24B-Gal80^ts^ \> dome^∆^* flies. We found an extremely strong increase in abundance of the 60 kDa form of total and activated (S505-phosphorylated) AKT ([Figure 1H,I](#fig1){ref-type="fig"}). This change was also seen in legs from *Mef2-Gal80^ts^ \> dome^∆^* flies, confirming that *dome* functions in muscles ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We also saw this effect in flies carrying a different insertion of the *dome^∆^* transgene, under the control of a third muscle-specific driver, *MHC-Gal4*, though the effect was weaker; the weakness of this effect may be a consequence of the fact that the MHC-Gal4 driver is not expressed in visceral muscle ([@bib8]) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). These *MHC-Gal4 \>dome^∆^ (II)* animals were also short-lived relative to controls ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

Elevated total AKT could result from increased transcript abundance or changes in protein production or stability. We distinguished between these possibilities by assaying *Akt1* mRNA; *Akt1* transcript levels were elevated in *24B-Gal80^ts^ \> dome^∆^* muscle, but only by about 75%, suggesting that the large effect on AKT protein abundance must be, at least in part, post-transcriptional ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Similarly, AKT hyperactivation could be driven by insulin-like peptide overexpression; however, we assayed the expression of *Ilp2-7* in whole flies and observed that none of these peptides were significantly overexpressed ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Next, we analysed if the feeding behaviour is affected by the muscle-specific *dome* loss, but we could not find a difference in food uptake in *24B-Gal80^ts^ \> dome^∆^* flies compared to controls ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

Unlike AKT, the amino-acid-responsive TORC1/S6K and the starvation-responsive AMPK pathway showed no significant difference in activity in *24B-Gal80^ts^ \> dome^∆^* flies ([Figure 1K,L](#fig1){ref-type="fig"}). However, flies with AMPK knocked down in muscle did exhibit mild AKT hyperactivation ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

To identify signalling mediators acting between Dome and AKT, we first tested activity of the MAPK-ERK pathway, which can act downstream of the JAK kinase Hop ([@bib22]). We found an insignificant reduction in ERK activity in *24B-Gal80^ts^ \> dome^∆^* flies ([Figure 1M](#fig1){ref-type="fig"}). We then assayed survival and AKT activity in flies with *hop* (JAK), *Dsor1* (MEK) and *rl* (ERK) knocked down in adult muscle. *rl* and *Dsor1* knockdown gave mild or no effect on survival and pAKT ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In contrast, *hop* knockdown gave a mild phenocopy of *dome^∆^* with regards to survival and pAKT ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

We further analysed the requirement for *hop* in muscle *dome* signalling by placing *24B-Gal80^ts^ \> dome^∆^* on a genetic background carrying the viable gain-of-function allele *hop^Tum-l^*. Flies carrying *hop^Tum-l^* alone exhibited no change in lifespan, AKT phosphorylation, or muscle lipid deposition ([Figure 2A--C](#fig2){ref-type="fig"}). However, *hop^Tum-l^* completely rescued lifespan and pAKT levels in *24B-Gal80^ts^ \> dome^∆^* flies ([Figure 2D,E](#fig2){ref-type="fig"}), indicating that the physiological activity of muscle Dome is mediated via Hop and that signal is required, but not sufficient, to control muscle AKT activity.

![Hop is required, but not sufficient, for Dome to control AKT.\
(**A**) Lifespan of *w^1118^* and *hop^Tum-L^* flies at 29°C. Log-Rank test: χ^2^ = 0.3223, ns p=0.5702; Wilcoxon test: χ^2^ = 0.4756, ns p=0.4906. (**B**) Phospho-AKT in leg samples from 14-day-old *w^1118^* and *hop^Tum-L^* flies. One experiment of two is shown. Unpaired T-Test: ns p=0.6854. (**C**) Actin (Phalloidin) and neutral lipid (LipidTox) in flight muscle from 14-day-old *w^1118^* and *hop^Tum-L^* flies. One representative fly shown of six analysed per genotype. Scale bar = 50 µm. (**D**) Lifespan of *24B-Gal80^ts^/+*, *24B-Gal80^ts^ \> dome^∆^*, and *hop^Tum-L^;24B-Gal80^ts^ \> dome^∆^* flies at 29°C. Log-Rank test (*24B-Gal80^ts^/+* vs. *24B-Gal80^ts^ \> dome^∆^*): χ^2^ = 319.4, \*\*\*p\<0.0001; Wilcoxon test (*24B-Gal80^ts^/+* vs. *24B-Gal80^ts^ \> dome^∆^*): χ^2^ = 280.2, \*\*\*p\<0.0001. Log-Rank test (*24B-Gal80^ts^/+* vs. *hop^Tum-L^ 24B-Gal80^ts^ \> dome^∆^*): χ^2^ = 18.87, \*\*\*p\<0.0001; Wilcoxon test (*24B-Gal80^ts^/+* vs. *hop^Tum-L^ 24B-Gal80^ts^ \> dome^∆^*): χ^2^ = 20.83, \*\*\*p\<0.0001. (**E**) Phospho-AKT in leg samples from 14-day-old *24B-Gal80^ts^/+*, *24B-Gal80^ts^ \> dome^∆^* and *hop^Tum-L^;24B-Gal80^ts^ \> dome^∆^* flies. P values from unpaired T-Test.](elife-51595-fig2){#fig2}

Increased AKT activity causes the effects of *dome* inhibition {#s2-3}
--------------------------------------------------------------

The phenotype of *24B-Gal80^ts^ \> dome^∆^* flies is similar to that previously described in flies with loss of function in *Pten* or *foxo* ([@bib14]; [@bib25]), suggesting that AKT hyperactivation might cause the *dome* loss of function phenotype; however, to our knowledge, direct activation of muscle AKT had not previously been analysed. We generated flies with inducible expression of activated AKT (*myr-AKT*) in adult muscles (*w;tubulin-Gal80^ts^/+;24B-Gal4/UAS-myr-AKT* \[*24B-Gal80^ts^ \> myr-AKT*\]) ([@bib31]). These animals phenocopied *24B-Gal80^ts^ \> dome^∆^* flies with regards to lifespan, climbing activity, metabolite levels, metabolic rate, and muscle lipid deposition ([Figure 3A--F](#fig3){ref-type="fig"}).

![AKT hyperactivation causes pathology in *24B-Gal80^ts^ \> dome^∆^* flies.\
(**A**) Lifespan of *24B-Gal80^ts^/+* and *24B-Gal80^ts^ \> myr*-AKT at 29°C. Log-Rank test: χ^2^ = 115.5, \*\*\*p\<0.0001; Wilcoxon test: χ^2^ = 123.6, \*\*\*p\<0.0001. (**B**) Negative geotaxis assay of 14-day-old *24B-Gal80^ts^/+* and *24B-Gal80^ts^ \> myr*-AKT flies. Points represent mean height climbed in individual vials (\~20 flies/vial), pooled from two independent experiments. Unpaired T-Test: \*p=0.018. (**C**) TLC of triglycerides in 7-day-old *24B-Gal80^ts^/+* and *24B-Gal80^ts^ \> myr*-AKT flies, n = 3--4 per genotype. One experiment of two is shown. Unpaired T-Test: \*p=0.0144. (**D**) Glucose and trehalose (left panel) and glycogen (right panel) in 7-day-old *24B-Gal80^ts^/+* (n = 12) and *24B-Gal80^ts^ \> myr*-AKT (n = 9) flies, pooled from two independent experiments. Unpaired T-Test (Glucose +Trehalose): \*\*\*p=0.0009 and unpaired T-Test (Glycogen): \*\*\*p\<0.0001. (**E**) CO~2~ produced, O~2~ consumed, and RQ of 7-day-old *24B-Gal80^ts^/+* and *24B-Gal80^ts^ \> myr*-AKT flies. Box plots show data from one representative experiment of three, with data points collected from a 24 hr measurement pooled from 3 to 4 tubes per genotype with 10 flies/tube. P values from Mann-Whitney test. (**F**) Phalloidin and LipidTox staining of thorax samples from 14-day-old *24B-Gal80^ts^/+* and *24B-Gal80^ts^ \> myr*-AKT flies. One representative fly per genotype is shown of 3 analysed per group in two independent experiments. Scale bar = 50 µm. (**G**) Lifespan of *24B-Gal80^ts^/+*, *24B-Gal80^ts^ \> dome^∆^*, *UAS-dome^Δ^/+, 24B-Gal80^ts^ \> AKT-*IR, *UAS-AKT-IR/+*, *24B-Gal80^ts^ \> AKT-IR;dome^∆^* and UAS-*AKT-IR;dome^∆^/+* flies at 29°C. Log-Rank test (*24B-Gal80^ts^ \> dome^∆^* vs. *24B-Gal80^ts^ \> AKT-IR;dome^∆^*): χ^2^ = 101.0, \*\*\*p\<0.0001; Wilcoxon test (*24B-Gal80^ts^ \> dome^∆^* vs. *24B-Gal80^ts^ \> AKT-IR;dome^∆^*): χ^2^ = 59.87, \*\*\*p\<0.0001. (**H**) Lifespan of *24B-Gal80^ts^/+*, *24B-Gal80^ts^ \> dome^∆^*, *foxo-GFP;24B-Gal80^ts^/+*, and *foxo-GFP;24B-Gal80^ts^ \> dome^∆^* flies at 29°C. Log-Rank test (*24B-Gal80^ts^ \> dome^∆^* vs. *foxo-GFP;24B-Gal80^ts^ \> dome^∆^*): χ^2^ = 114.0, \*\*\*p\<0.0001; Wilcoxon test (*24B-Gal80^ts^ \> dome^∆^* vs. *foxo-GFP;24B-Gal80^ts^ \> dome^∆^*): χ^2^ = 93.59, \*\*\*p\<0.0001. (**I**) Glucose + trehalose and glycogen in 7-day-old *24B-Gal80^ts^/+*, *24B-Gal80^ts^ \> dome^Δ^*, *foxo-GFP;24B-Gal80/+*, and foxo-GFP; *24B-Gal80^ts^ \> dome^Δ^* flies. Statistical testing was performed with one-way ANOVA. (**J**) TLC of triglycerides in 7-day-old *24B-Gal80^ts^/+*, *24B-Gal80^ts^ \> dome^Δ^*, *foxo-GFP;24B-Gal80^ts^/+*, and *foxo-GFP;24B-Gal80^ts^ \> dome^Δ^* flies. Statistical testing was performed with one-way ANOVA.](elife-51595-fig3){#fig3}

We concluded that AKT hyperactivation could cause the pathologies seen in *24B-Gal80^ts^ \> dome^∆^* flies. Therefore, we tested whether reducing AKT activity could rescue *24B-Gal80^ts^ \> dome^∆^* flies. We generated flies carrying muscle-specific inducible dominant negative dome (*UAS-dome^∆^*) with dsRNA against *Akt1* (*UAS-AKT-IR*). These flies showed significantly longer lifespan than *24B-Gal80^ts^ \> dome^∆^* and *24B-Gal80^ts^ \> AKT* IR flies, similar to all control genotypes analyzed ([Figure 3G](#fig3){ref-type="fig"}). Dome and AKT antagonism synergised to control the mRNA level of *dome* itself, further suggesting strong mutual antagonism between these pathways ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

AKT hyperactivation should reduce FOXO transcriptional activity. To test whether this loss of FOXO activity caused some of the pathologies observed in *24B-Gal80^ts^ \> dome^∆^* flies, we increased *foxo* gene dosage by combining *24B-Gal80^ts^ \> dome^∆^* with a transgene carrying a FOXO-GFP fusion protein under the control of the endogenous *foxo* regulatory regions. These animals exhibited rescue of physiological defects and lifespan compared to *24B-Gal80^ts^ \> dome^∆^* flies ([Figure 3H--J](#fig3){ref-type="fig"}). They also exhibited increased *dome* expression ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The effects of these manipulations on published *foxo* target genes were mixed ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}); the strongest effect we observed was that Dome blockade increased *upd2* expression ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), consistent with the observation that FOXO activity inhibits *upd2* expression in muscle (none of the other genes tested have been shown to be FOXO targets in muscle) ([@bib39]). This may explain some of the systemic effects of Dome blockade.

The effect of the *foxo* transgene was stronger than expected from a 1.5-fold increase in *foxo* expression, so we further explored the relationship between FOXO protein expression and AKT phosphorylation. We found that *24B-Gal80^ts^ \> dome^∆^* markedly increased FOXO-GFP abundance, so that the increase in total FOXO was much greater than 1.5-fold ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). This drove an apparent feedback effect, restoring AKT in leg samples of *foxo^GFP^;24B-Gal80^ts^ \> dome^∆^* flies to near-normal levels ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

We also analysed expression of the catabolic hormone Akh and its putative targets *bmm*, *Hsl*, *plin1* and *plin2* in *24B-Gal80^ts^ \> dome^∆^* animals ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). We observed no clear regulation of *Akh* itself or of *Hsl*, *bmm*, or *plin2; plin1* was reduced in expression by expression of *dome^∆^*. We conclude that the primary effect of muscle *dome* is on AKT-foxo signalling.

Plasmatocytes are a relevant source of *upd* signals {#s2-4}
----------------------------------------------------

Plasmatocytes---*Drosophila* macrophages---are a key source of *upd3* in flies on high fat diet and in mycobacterial infection ([@bib28]; [@bib36]). Plasmatocytes also express *upd1-3* in unchallenged flies ([@bib12]). We thus tested their role in activation of muscle Dome.

We found plasmatocytes close to STAT-GFP-positive leg muscle ([Figure 4A,B](#fig4){ref-type="fig"}). This, and the prior published data, suggested that plasmatocytes might produce relevant levels of *dome-*activating cytokines in steady state. We then overexpressed *upd3* in plasmatocytes and observed a potent increase in muscle STAT-GFP activity ([Figure 4C](#fig4){ref-type="fig"}), confirming that plasmatocyte-derived *upd* signals were able to activate muscle Dome.

![Plasmatocytes promote muscle Dome activity.\
(**A**) Muscle (*MHC^YFP^*) and plasmatocytes (*srpHemo-3xmCherry*) in 7-day-old flies. Plasmatocytes are found in close proximity to adult muscles. One representative fly of 5 is shown. Scale bar = 500 µm. (**B**) Legs and plasmatocytes in 7-day-old *10xSTAT92E-GFP;srpHemo-3xmCherry* flies. Muscle with high JAK-STAT activity (green) is surrounded by plasmatocytes (magenta). One representative fly of 5 is shown. Scale bar = 100 µm. (**C**) STAT activity and plasmatocytes in legs from control (*10xSTAT92E-GFP;crq-Gal4 \>CD8-mCherry/+*) and *upd3*-overexpressing (*10xSTAT92E-GFP;crq-4\>CD8mCherry/UAS-upd3*) flies. One representative fly of 10--14 is shown. Scale bar = 100 µm. Graph shows mean fluorescence intensity (MFI). Unpaired T-Test: \*\*\*p\<0.0001. (**D**) STAT activity and plasmatocytes in legs from control (*10xSTAT92E-GFP;crq-Gal80^ts^ \> CD8-mCherry/+*) and plasmatocyte-depleted (*10xSTAT92E-GFP;crq-Gal80^ts^ \> CD8* mCherry/rpr) flies. One representative fly of six is shown. Scale bar = 250 µm. (**E**) Western blot analysis of STAT-driven GFP in legs from 7-day-old control (*10xSTAT92E-GFP;crq-Gal80^ts^ \> CD8-mCherry/+*) and plasmatocyte-depleted (*10xSTAT92E-GFP;crq-Gal80^ts^ \> CD8* mCherry/rpr flies). One representative experiment of three is shown. Graph shows STAT-GFP/α-tubulin for control (*crq-Gal80^ts^/+*) and plasmatocyte-depleted (*crq-Gal80^ts^ \> rpr*) leg samples. Unpaired T-Test: \*p=0.0121. (**F**) Lifespan of *crq-Gal80^ts^/+*, *crq-Gal80^ts^ \> rpr*, *upd2^Δ^ upd3^Δ^;crq-Gal80^ts^/+*, and *upd2^Δ^ upd3^Δ^;crq-Gal80^ts^ \> rpr* flies at 29°C. Log-Rank test (*crq-Gal80^ts^/+* vs. *crq-Gal80^ts^ \> rpr*): χ2 = 101.7, \*\*\*p\<0.0001; Wilcoxon test (*crq-Gal80^ts^/+* vs. *crq-Gal80^ts^ \> rpr*): χ2 = 107.8, \*\*\*p\<0.0001; Log-Rank test (*crq-Gal80^ts^/+* vs. *upd2 ^Δ^ upd3^Δ^;crq-Gal80^ts^ \> rpr*): χ2 = 60.03, \*\*\*p\<0.0001; Wilcoxon test (*crq-Gal80^ts^/+* vs. *upd2 ^Δ^ upd3^Δ^;crq-Gal80^ts^ \> rpr*): χ2 = 80.97, \*\*\*p\<0.0001. (**G**) Actin (Phalloidin) and neutral lipid (LipidTox) in thorax samples from 14-day-old *crq-Gal80^ts^/+*, *crq-Gal80^ts^ \> rpr*, *upd2 ^Δ^ upd3^Δ^;crq-Gal80^ts^/+*, and *upd2 ^Δ^ upd3^Δ^;crq-Gal80^ts^ \> rpr* flies. One representative fly per genotype shown of 6 analysed per group. Scale bar = 50 µm. (**H**) Lifespan of *crq-Gal4/+* and *crq-Gal4 \>upd1* IR flies at 29°C. Log-Rank test: χ2 = 31.36, \*\*\*p\<0.0001; Wilcoxon test: χ2 = 22.17, \*\*\*p=0.0001. (**I**) Expression by qRT-PCR of *upd1*, *upd2* and *upd3* in thorax samples of *crq-Gal4/+* and *crq-Gal4 \>upd1* IR flies, data from four independent samples of each genotype.. Unpaired T-Test (*upd1*): ns p=0.848, unpaired T-Test (*upd2*): \*p*=0.0449* and unpaired T-Test (*upd3*): \*\*p=0.0038. (**J**) Lifespan of *crq-Gal4/+*, *upd2 ^Δ^ upd3^Δ^;UAS-upd1-IR/+*, and *upd2^Δ^ upd3^Δ^;crq-Gal4 \>upd1* IR flies at 29°C. Log-Rank test (*crq-Gal4/+* vs. *upd2 ^Δ^ upd3^Δ^;crq-Gal4 \>upd1* IR): χ2 = 41.12, \*\*\*p\<0.0001; Wilcoxon test (*crq-Gal4/+* vs. *upd2^Δ^ upd3^Δ^;crq-Gal4 \>upd1* IR): χ2 = 54.47, \*\*\*p\<0.0001 Log-Rank test (*crq-Gal4/+* vs. *upd2 ^Δ^ upd3^Δ^;UAS-upd1-IR/+*): χ2 = 14.46, \*\*\*p\<0.0001; Wilcoxon test (*crq-Gal4/+* vs. *upd2^Δ^ upd3^Δ^;UAS-upd1-IR/+*): χ2 = 19.99, \*\*\*p\<0.0001. P values in C, E, H from unpaired T-test.](elife-51595-fig4){#fig4}

To determine the physiological relevance of plasmatocyte-derived signals, we assayed STAT-GFP activity in flies in which plasmatocytes had been depleted by expression of the pro-apoptotic gene *reape*r (*rpr*) using a temperature-inducible plasmatocyte-specific driver line (*w;tub-Gal80^ts^;crq-Gal4*). These animals exhibited a near-complete elimination of plasmatocytes within 24 hr of being shifted to 29°C ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). STAT-GFP fluorescence and GFP abundance were reduced in legs of plasmatocyte-depleted flies (*crq-Gal80^ts^ \> rpr*) compared to controls (*crq-Gal80^ts^/+*) ([Figure 4D,E](#fig4){ref-type="fig"}). Activity was not eliminated, indicating that plasmatocytes are not the only source of muscle STAT-activating signals, although these animals did exhibit a significant reduction in climbing activity ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

We then examined the lifespan of flies in which we had depleted plasmatocytes in combination with various *upd* mutations and knockdowns. Plasmatocyte depletion gave animals that were short-lived ([Figure 4F](#fig4){ref-type="fig"}). (This effect was different from that we previously reported, possibly due to changes in fly culture associated with an intervening laboratory move \[[@bib36]\]). Combining plasmatocyte depletion with null mutations in *upd2* and *upd3* did not significantly further reduce lifespan; *upd2 upd3* mutants with plamatocytes intact exhibited near-normal lifespan ([Figure 4F](#fig4){ref-type="fig"}). Similarly, plasmatocyte depletion drove muscle lipid accumulation, and *upd2 upd3* mutation synergised with plasmatocyte depletion to further increase muscle lipid inclusions ([Figure 4G](#fig4){ref-type="fig"}). Plasmatocyte depletion reduced free sugar levels as well as glycogen levels in the whole fly ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), but did not reduce the abundance of stored triglycerides ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). However, depleting plasmatocytes in *upd2 upd3* mutants failed to recapitulate the effects of muscle Dome inhibition on whole-animal triglyceride, free sugar, and glycogen levels ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). This could be due to antagonistic effects of other plasmatocyte-derived signals.

We attempted to pinpoint a specific Upd as the relevant physiological ligand by examining STAT-GFP activity, first testing mutants in *upd2* and *upd3* because *upd1* mutation is lethal. However, these mutants, including the *upd2 upd3* double-mutant, were apparently normal ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). We then tested plasmatocyte-specific knockdown of *upd1* and *upd3*; these animals were also essentially normal ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), and plasmatocyte *upd1* knockdown did not reduce lifespan ([Figure 4H](#fig4){ref-type="fig"}). However, plasmatocyte-specific *upd1* knockdown gave significant compensating increases in expression of *upd2* and *upd3* ([Figure 4I](#fig4){ref-type="fig"}). In keeping with this, combining plasmatocyte-specific *upd1* knockdown with mutations in *upd2* and *upd3* reduced lifespan ([Figure 4J](#fig4){ref-type="fig"}) and also reduced STAT-GFP activity in these flies ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

Our results indicate that plasmatocytes are an important physiological source of the Upd signal driving muscle Dome activity in healthy flies, and suggest that *upd1* may be the primary relevant signal in healthy animals. However, plasmatocytes are not the only relevant source of signal, and Upd mutual regulation prevents us from pinpointing a single responsible signal.

Discussion {#s3}
==========

Here we show that *upd-dome* signalling in muscle acts via AKT to regulate physiological homeostasis in *Drosophila*. Loss of Dome activity in adult muscles shortens lifespan and promotes local and systemic metabolic disruption. Dome specifically regulates the level and activity of AKT; AKT hyper-activation mediates the observed pathology. Plasmatocytes are a primary source of the cytokine signal. In healthy adult flies, insulin-like peptides are the primary physiological AKT agonists. The effect we observe thus appears to be an example of a cytokine-Dome-JAK signal that impairs insulin function to permit healthy physiology.

Our work fits into a recent body of literature demonstrating key physiological roles for JAK-STAT activating signals in *Drosophila*. Upd1 acts locally in the brain to regulate feeding and energy storage by altering the secretion of neuropeptide F (NPF) ([@bib6]). Upd2 is released by the fat body in response to dietary triglyceride and sugar to regulate secretion of insulin-like peptides ([@bib29]). More recently, muscle-derived Upd2, under control of FOXO, has been shown to regulate production of the glucagon-like signal Akh ([@bib39]). Indeed, we observe that *upd2* is upregulated in flies with Dome signalling blocked in muscle, possibly explaining some of the systemic metabolic effects we observe. Plasmatocyte-derived Upd3 in flies on a high fat diet can activate the JAK/STAT pathway in various organs including muscles and can promote insulin insensitivity ([@bib36]). Our observation that Upd signalling is required to control AKT accumulation and thus insulin pathway activity in healthy adult muscle may explain some of these prior observations and reveals a new role for plasmatocyte-derived cytokine signalling in healthy metabolic regulation.

Several recent reports have examined roles of JAK/STAT signalling in *Drosophila* muscle. In larvae, muscle JAK/STAT signalling can have an effect opposite to the one we report, with pathway loss of function resulting in reduced AKT activity ([@bib38]). It is unclear whether this difference represents a difference in function between developmental stages (larva vs adult) or a difference between acute and chronic consequences of pathway inactivation. Roles in specific muscle populations have also been described: for example, JAK/STAT signalling in adult visceral muscle regulates expression of Vein, an EGF-family ligand, to control intestinal stem cell proliferation ([@bib11]; [@bib19]); the role of this system in other muscles may be analogous, controlling expression of various signals to regulate systemic physiology. Importantly, though we do not observe loss of gut integrity in our flies, it remains possible that the gut is an important mediator of some aspect of the physiological *unpaired* signal we document---either acting as an endocrine relay or via more subtle effects on gut physiology that could affect nutrient absorption. This would fit our observation that expression of dominant-negative *Dome* under the control of Mhc-Gal4 (which does not express in visceral muscle) gives a weaker effect on survival and AKT abundance than other muscle drivers and is particularly of interest given the documented role of plasmatocytes in regulation of gut homeostasis ([@bib3]).

The roles of mammalian JAK/STAT signalling in muscle physiology are more complex, but exhibit several parallels with the fly. In mice, early muscle-specific deletion of Growth Hormone Receptor (GHR) causes several symptoms including insulin resistance, while adult muscle-specific GHR deletion causes entirely different effects, including increased metabolic rate and insulin sensitivity on a high-fat diet ([@bib24]; [@bib34]; [@bib33]). GHR signals via STAT5; STAT5 deletion in adult skeletal muscle promotes muscle lipid accumulation on a high-fat diet ([@bib5]). Other STAT pathways can also play roles. For example, the JAK-STAT activating cytokine IL-6, which signals primarily via STAT3, increases skeletal muscle insulin sensitivity when given acutely but can drive insulin resistance when provided chronically ([@bib27]). STAT3 itself can promote muscle insulin resistance ([@bib20]; [@bib23]). The relationship between these effects and those we have shown here, and the mechanisms regulating Upd production by plasmatocytes during healthy physiology, remain to be determined.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                         Designation                                               Source or reference                          Identifiers                                                                                   Additional\
  (species) or resource                                                                                                                                                                                                                      information
  ------------------------------------- --------------------------------------------------------- -------------------------------------------- --------------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  Genetic reagent\                      *w^1118^; tubulin-Gal80^ts^/SM6a;24B-Gal4/TM6c, Sb^1^*    This study                                                                                                                                 Inserted Elements: P\[w\[+mC\]=tubP-GAL80\[ts\]\]; P\[GawB\]how24B
  (*D. melanogaster*)                                                                                                                                                                                                                        

  Genetic reagent (*D. melanogaster*)   *w^1118^; tubulin-Gal80^ts^/SM6a;Mef2-Gal4/TM6c, Sb^1^*   This study                                                                                                                                 Inserted Elements: P\[w\[+mC\]=tubP-GAL80\[ts\]\]; P\[GAL4-Mef2.R\]3

  Genetic reagent (*D. melanogaster*)   *w^1118^;;UAS-dome^∆^/TM6c, Sb^1^*                        [@bib10]                                                                                                                                   Gift of James Castelli-Gair Hombría

  Genetic reagent (*D. melanogaster*)   *w^1118^;UAS-dome^∆^/CyO*                                 [@bib10]                                                                                                                                   Gift of James Castelli-Gair Hombría

  Genetic reagent (*D. melanogaster*)   *w^1118^;;UAS-myr-AKT/TM6c, Sb^1^*                        [@bib31]                                                                                                                                   Gift of Ernst Hafen

  Genetic reagent (*D. melanogaster*)   *w;UAS-AMPKα-IR*                                          Vienna *Drosophila* Research Center (VDRC)   RRID:[FlyBase_FBst0478025](https://scicrunch.org/resolver/FlyBase_FBst0478025); VDRC 106200   

  Genetic reagent (*D. melanogaster*)   *w;UAS-AMPKβ-IR*                                          VDRC                                         RRID:[FlyBase_FBst0476347](https://scicrunch.org/resolver/FlyBase_FBst0476347); VDRC 104489   

  Genetic reagent (*D. melanogaster*)   *w;UAS-rl-IR*                                             VDRC                                         RRID:[FlyBase_FBst0480887](https://scicrunch.org/resolver/FlyBase_FBst0480887); VDRC 109108   

  Genetic reagent (*D. melanogaster*)   *w;UAS-Dsor1-IR*                                          VDRC                                         RRID:[FlyBase_FBst0479098](https://scicrunch.org/resolver/FlyBase_FBst0479098); VDRC 107276   

  Genetic reagent (*D. melanogaster*)   *w^1118^;foxo^GFP^*                                       BDSC                                         RRID:[BDSC_38644](https://scicrunch.org/resolver/BDSC_38644)                                  Inserted Element:\
                                                                                                                                                                                                                                             PBac\[foxo-GFP.FLAG\]VK00037

  Genetic reagent (*D. melanogaster*)   *w;UAS-AKT-IR*                                            VDRC                                         RRID:[FlyBase_FBst0475561](https://scicrunch.org/resolver/FlyBase_FBst0475561); VDRC 103703   

  Genetic reagent (*D. melanogaster*)   *w^1118^;10xSTAT92E-GFP*                                  BDSC\                                        RRID:[BDSC_26197](https://scicrunch.org/resolver/BDSC_26197)                                  Inserted Element:\
                                                                                                  [@bib4]                                                                                                                                    P\[10XStat92E-GFP\]1

  Genetic reagent (*D. melanogaster*)   *w^1118^;MHC-Gal4*,*MHC-RFP/SM6a*                         BDSC                                         RRID:[BDSC_38464](https://scicrunch.org/resolver/BDSC_38464)                                  Inserted Element:\
                                                                                                                                                                                                                                             P\[Mhc-GAL4.F3-580\]2; P\[Mhc-RFP.F3-580\]2

  Genetic reagent (*D. melanogaster*)   *w upd2 ^Δ^ upd3^Δ^;;;*                                   BDSC                                         RRID:[BDSC_55729](https://scicrunch.org/resolver/BDSC_55729)                                  

  Genetic reagent (*D. melanogaster*)   *w^1118^;;crq-Gal4/TM6 c, Sb^1^*                                                                                                                                                                     Gift of Nathalie Franc

  Genetic reagent (*D. melanogaster*)   *w^1118^;tub-Gal80^ts^;TM2/TM6 c, Sb^1^*                  BDSC                                         RRID:[BDSC_7108](https://scicrunch.org/resolver/BDSC_7108)                                    

  Genetic reagent (*D. melanogaster*)   *w^1118^;;UAS-rpr/TM6 c, Sb^1^*                           BDSC                                         RRID:[BDSC_5824](https://scicrunch.org/resolver/BDSC_5824)                                    

  Genetic reagent (*D. melanogaster*)   *w^1118^;UAS-CD8-mCherry*                                 BDSC                                         RRID:[BDSC_27391](https://scicrunch.org/resolver/BDSC_27391)                                  

  Genetic reagent (*D. melanogaster*)   *w^1118^;;srpHemo-3xmCherry/TM6c, Sb^1^*                  [@bib16]                                                                                                                                   

  Genetic reagent (*D. melanogaster*)   *w;UAS-hop-IR*                                            VDRC                                         RRID:[FlyBase_FBst0463355](https://scicrunch.org/resolver/FlyBase_FBst0463355); VDRC 40037    

  Genetic reagent (*D. melanogaster*)   *w;UAS-upd1-IR/SM6a*                                      VDRC                                         RRID:[FlyBase_FBst0459787](https://scicrunch.org/resolver/FlyBase_FBst0459787); VDRC 3282     

  Genetic reagent (*D. melanogaster*)   *w;UAS-upd3-IR*                                           VDRC                                         RRID:[FlyBase_FBst0456774](https://scicrunch.org/resolver/FlyBase_FBst0456774); VDRC 27134    

  Genetic reagent (*D. melanogaster*)   *w^1118^;;UAS-upd3/TM6 c, Sb^1^*                                                                                                                                                                     Gift of Bruce Edgar

  Genetic reagent (*D. melanogaster*)   *w^1118^;UAS-2xeGFP/SM6a*                                 BDSC                                         RRID:[BDSC_6874](https://scicrunch.org/resolver/BDSC_6874)                                    

  Genetic reagent (*D. melanogaster*)   *w^1118^ hop^Tum-L^/FM7h*                                 BDSC                                         RRID:[BDSC_8492](https://scicrunch.org/resolver/BDSC_8492)                                    backcrossed onto *w^1118^* background

  Sequence-based reagent                Akt1_forward                                              This study                                   PCR primers                                                                                   5'-ctttgcgagtattaactggacaga-3'

  Sequence-based reagent                Akt1_reverse                                              This study                                   PCR primers                                                                                   5'-ggatgtcacctgaggcttg-3'

  Sequence-based reagent                Ilp2_forward                                              This study                                   PCR primers                                                                                   5'-atcccgtgattccaccacaag-3'

  Sequence-based reagent                Ilp2_reverse                                              This study                                   PCR primers                                                                                   5'-gcggttccgatatcgagtta-3'

  Sequence-based reagent                Ilp3_forward                                              This study                                   PCR primers                                                                                   5'-caacgcaatgaccaagagaa-3'

  Sequence-based reagent                Ilp3_reverse                                              This study                                   PCR primers                                                                                   5'-tgagcatctgaaccgaact-3'

  Sequence-based reagent                Ilp4_forward                                              This paper                                   PCR primers                                                                                   5'-gagcctgattagactgggactg-3'

  Sequence-based reagent                Ilp4_reverse                                              This paper                                   PCR primers                                                                                   5'-tggaccggctgcagtaac-3'

  Sequence-based reagent                Ilp5_forward                                              This paper                                   PCR primers                                                                                   5'-gccttgatggacatgctga-3'

  Sequence-based reagent                Ilp5_reverse                                              This paper                                   PCR primers                                                                                   5'-agctatccaaatccgcca-3'

  Sequence-based reagent                Ilp6_forward                                              This paper                                   PCR primers                                                                                   5'-cccttggcgatgtatttcc-3'

  Sequence-based reagent                Ilp6_reverse                                              This paper                                   PCR primers                                                                                   5'-cacaaatcggttacgttctgc-3'

  Sequence-based reagent                Ilp7_forward                                              This paper                                   PCR primers                                                                                   5'-cacaccgaggagggtctc-3'

  Sequence-based reagent                Ilp7_reverse                                              This paper                                   PCR primers                                                                                   5'-caatatagctggcggacca-3'

  Sequence-based reagent                dome_forward                                              This paper                                   PCR primers                                                                                   5'-cggactttcggtactccatc-3'

  Sequence-based reagent                dome_reverse                                              This paper                                   PCR primers                                                                                   5'-accttgatgaggccaggat-3'

  Sequence-based reagent                upd1_forward                                              This paper                                   PCR primers                                                                                   5'-gcacactgatttcgatacgg-3'

  Sequence-based reagent                upd1_reverse                                              This paper                                   PCR primers                                                                                   5'- ctgccgtggtgctgtttt −3'

  Sequence-based reagent                upd2_forward                                              This paper                                   PCR primers                                                                                   5'-cggaacatcacgatgagcgaat-3'

  Sequence-based reagent                upd2_reverse                                              This paper                                   PCR primers                                                                                   5'-tcggcaggaacttgtactcg-3'

  Sequence-based reagent                upd3_forward                                              This paper                                   PCR primers                                                                                   5'-actgggagaacacctgcaat-3'

  Sequence-based reagent                upd3_reverse                                              This paper                                   PCR primers                                                                                   5'-gcccgtttggttctgtagat-3'

  Sequence-based reagent                Pepck_forward                                             This paper                                   PCR primers                                                                                   5'-ggataaggtggacgtgaag-3'

  Sequence-based reagent                Pepck_reverse                                             This paper                                   PCR primers                                                                                   5'-acctcctgcgaccagaact-3'

  Sequence-based reagent                Thor_forward                                              This paper                                   PCR primers                                                                                   5'-caggaaggttgtcatctcgga-3'

  Sequence-based reagent                Thor_reverse                                              This paper                                   PCR primers                                                                                   5'-ggagtggtggagtagagggtt-3'

  Sequence-based reagent                InR_forward                                               This paper                                   PCR primers                                                                                   5\'-gcaccattataaccggaacc-3\'

  Sequence-based reagent                InR_reverse                                               This paper                                   PCR primers                                                                                   5\'-ttaattcatccatgacgtgagc-3\'

  Sequence-based reagent                Akh_forward                                               This paper                                   PCR primers                                                                                   5'- agccgtgctcttcatgct-3'

  Sequence-based reagent                Akh_reverse                                               This paper                                   PCR primers                                                                                   5'-aaaggttccaggaccagctc-3'

  Sequence-based reagent                Hsl_forward                                               This paper                                   PCR primers                                                                                   5'-cttggaaatacttgaggggttg-3'

  Sequence-based reagent                Hsl_reverse                                               This paper                                   PCR primers                                                                                   5'-agatttgatgcagttctttgagc-3'

  Sequence-based reagent                bmm_forward                                               This paper                                   PCR primers                                                                                   5'-gtctcctctgcgatttgccat-3'

  Sequence-based reagent                bmm_reverse                                               This paper                                   PCR primers                                                                                   5'-ctgaagggacccagggagta-3'

  Sequence-based reagent                plin1_forward                                             This paper                                   PCR primers                                                                                   5'-gcgttctatggtagccttcag-3'

  Sequence-based reagent                plin1_reverse                                             This paper                                   PCR primers                                                                                   5'-gcgtccggatagaaagctg-3'

  Sequence-based reagent                plin2_forward                                             This paper                                   PCR primers                                                                                   5'-gcagaatggcaagagttctga-3'

  Sequence-based reagent                plin2_reverse                                             This paper                                   PCR primers                                                                                   5'-actgtgtgtaggactggatcctc-3'

  Sequence-based reagent                Rpl1_forward                                              This paper                                   PCR primers                                                                                   5'-tccaccttgaagaagggcta-3'

  Sequence-based reagent                Rpl1_reverse                                              This paper                                   PCR primers                                                                                   5'-ttgcggatctcctcagactt-3'

  Peptide, recombinant protein          Trehalase                                                 Sigma Aldrich                                T8778                                                                                         

  Peptide, recombinant protein          β-Amyloglucosidase                                        Sigma Aldrich                                10115                                                                                         

  Antibody                              anti-phospho(Ser505)-AKT                                  Cell Signal Technology (CST)                 Cat\# 4054; RRID:[AB_331414](https://scicrunch.org/resolver/AB_331414)                        WB (1:1000)

  Antibody                              anti-AKT                                                  Cell Signal Technology (CST)                 Cat\# 4691; RRID:[AB_915783](https://scicrunch.org/resolver/AB_915783)                        WB (1:1000)

  Antibody                              anti-phospho(Thr172)-AMPKα                                Cell Signal Technology (CST)                 Cat\# 2535; RRID:[AB_331250](https://scicrunch.org/resolver/AB_331250)                        WB (1:1000)

  Antibody                              anti-phospho(Thr389)-p70 S6 kinase                        Cell Signal Technology (CST)                 Cat\# 9206; RRID:[AB_2285392](https://scicrunch.org/resolver/AB_2285392)                      WB (1:1000)

  Antibody                              anti-GFP                                                  Cell Signal Technology (CST)                 Cat\# 2956; RRID:[AB_1196615](https://scicrunch.org/resolver/AB_1196615)                      WB (1:1000)

  Antibody                              anti-phospho-p44/42 MAPK (Erk1/2)                         Cell Signal Technology (CST)                 Cat\# 4370; RRID:[AB_2315112](https://scicrunch.org/resolver/AB_2315112)                      WB (1:1000)

  Antibody                              anti-α-tubulin                                            Developmental Studies Hybridoma Bank)        Clone 12G10; RRID:[AB_1157911](https://scicrunch.org/resolver/AB_1157911)                     WB (1:3000)

  Antibody                              HRP anti-rabbit IgG                                       Cell Signal Technology (CST)                 Cat\# 7074; RRID:[AB_2099233](https://scicrunch.org/resolver/AB_2099233)                      WB (1:5000)

  Antibody                              HRP anti-mouse IgG                                        Cell Signal Technology (CST)                 Cat\# 7076; RRID:[AB_330924](https://scicrunch.org/resolver/AB_330924)                        WB (1:5000)

  Commercial assay or kit               First Strand cDNA Synthesis Kit                           Thermo Scientific                            K1622                                                                                         

  Commercial assay or kit               Sensimix SYBR Green no-ROX                                Bioline                                      QT650-05                                                                                      

  Chemical compound, drug               Bromophenol blue                                          Sigma Aldrich                                SML1656                                                                                       

  Chemical compound, drug               Xylene cyanol                                             Carl Roth                                    A513.1                                                                                        

  Chemical compound, drug               Brilliant Blue FCF                                        Sigma Aldrich                                80717                                                                                         

  Other                                 HCS Lipid Tox Deep Red                                    Thermo Fisher                                H34477                                                                                        IF (1:200)

  Other                                 Alexa Fluor 488 Phalloidin                                Thermo Fisher                                A12379                                                                                        IF (1:20)

  Other                                 Fluoromount-G                                             ebioscience                                  00-4958-02                                                                                    

  Other                                 TRIzol                                                    Invitrogen                                   AM9738                                                                                        

  Other                                 Fixable Viability Dye 780                                 ebioscience                                  65-0865-18                                                                                    FC (1:1000)

  Other                                 Supersignal West Pico Chemiluminescent Substrate          Thermo Scientific                            34077                                                                                         

  Other                                 Supersignal West Femto Chemiluminescent Substrate         Thermo Scientific                            34094                                                                                         

  Other                                 Glucose Reagent                                           Sentinel Diagnostics                         17630H                                                                                        

  Software, algorithm                   ImageJ                                                    ImageJ                                       RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)                                  

  Software, algorithm                   GraphPad Prism                                            GraphPad                                     RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                                  

  Software, algorithm                   FlowJo                                                    FlowJo                                       RRID:[SCR_008520](https://scicrunch.org/resolver/SCR_008520))                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Drosophila melanogaster* stocks and culture {#s4-1}
--------------------------------------------

All fly stocks were maintained on food containing 10% w/v Brewer's yeast, 8% fructose, 2% polenta and 0.8% agar supplemented with propionic acid and nipagin. Crosses for experiments were performed at 18°C (for crosses with temperature inducible gene expression) or 25°C. Flies were shifted to 29°C after eclosion where relevant.

Male flies were used for all experiments. All flies were backcrossed onto our laboratory isogenic *w^1118^* genetic background, with the exception of VDRC knockdown lines (these lines are also on a uniform genetic background and could be compared with one another). All crosses were performed using driver females so that the male progeny used for experiments would have a uniform X chromosome.

The following original fly stocks were used for crosses:

Fly stocksDescription and origin*w^1118^; tubulin-Gal80^ts^/SM6a;24B-Gal4/TM6c, Sb^1^*Temperature sensitive muscle specific driver line; 24B-Gal4 a gift of Nazif Alic*w^1118^; tubulin-Gal80^ts^/SM6a;Mef2-Gal4/TM6c, Sb^1^*Temperature sensitive muscle specific driver line; Mef2-Gal4 a gift of Michael Taylor*w^1118^;;UAS-dome^∆^/TM6c, Sb^1^*Line for expression of a dominant-negative *dome*, gift of James Castelli-Gair Hombría*w^1118^;UAS-dome^∆^/CyO*Line for expression of a dominant-negative *dome*, gift of James Castelli-Gair Hombría*w^1118^;;UAS-myr-AKT/TM6c, Sb^1^*Line for over-expression of a constitutive active (myristoylated) AKT, gift of Ernst Hafen*w;UAS-AMPKα-IR*VDRC KK106200*w;UAS-AMPKβ-IR*VDRC KK104489*w;UAS-rl-IR*VDRC KK109108*w;UAS-Dsor1-IR*VDRC KK102276*w^1118^;foxo^GFP^*Expresses GFP-tagged *foxo* fusion protein (genomic rescue construct inserted at AttP40). Bloomington *Drosophila* Stock Center (BDSC) 38644*w;UAS-AKT-IR*VDRC KK103703*w^1118^;10xSTAT92E-GFP*STAT-GFP reporter line ([@bib4]). BDSC \#26197*w^1118^;MHC-Gal4,MHC-RFP/SM6a*Muscle specific driver line and muscle specific reporter line. Derived from BDSC \#38464*w upd2 ^Δ^ upd3^Δ^;;;*Gift of Bruno Lemaitre*w^1118^;;crq-Gal4/TM6c, Sb^1^*Plasmatocyte specific driver line, gift of Nathalie Franc*w^1118^;tub-Gal80^ts^;TM2/TM6c, Sb^1^*Line for ubiquitous expression of *Gal80^ts^*, BDSC \#7108*w^1118^;;UAS-rpr/TM6c, Sb^1^*Line for over-expression of the pro-apoptotic protein rpr. Derived from BDSC \#5824*w^1118^;UAS-CD8-mCherry*Line for overexpression of a CD8-mCherry fusion protein. Derived from BDSC \#27391*w^1118^;;srpHemo-3xmCherry/TM6c, Sb^1^*Plasmatocyte reporter line ([@bib16])*w;UAS-hop-IR*VDRC GD40037*w;UAS-upd1-IR/SM6a*VDRC GD3282*w;UAS-upd3-IR*VDRC GD6811*w^1118^;;UAS-upd3/TM6c, Sb^1^*Line for overexpression of upd3, gift of Bruce Edgar*w^1118^;UAS-2xeGFP/SM6a*Line for expression of bicistronic GFP, BDSC \#6874*w^1118^ hop^Tum-L^/FM7h*Gain-of function mutant of *hop*; derived by backcrossing from BDSC 8492 onto our control *w^1118^* background

Genotype abbreviations were used for the different experimental flies in this study, in the following table the complete genotypes are indicated:

Genotype abbreviation of flies used in the manuscriptComplete genotype of flies used in the manuscript*10XSTAT92E-GFP/MHC-RFPw^1118^;10xSTAT92E-GFP/MHC-Gal4,MHC-RFP24B-Gal80^ts^/+w^1118^;tub-Gal80^ts^/+;24B-Gal4/+24B-Gal80^ts^ \> dome^∆^w^1118^;tub-Gal80^ts^/+;24B-Gal4/UAS-dome^∆^24B-Gal80^ts^ \> myr-AKTw^1118^;tub-Gal80^ts^/+;24B-Gal4/UAS-myr-AKT24B-Gal80^ts^ \> AMPKα-IRw^1118^;tub-Gal80^ts^/UAS-AMPKα-IR;24B-Gal4/+24B-Gal80^ts^ \> AMPKβ-IRw^1118^;tub-Gal80^ts^/UAS-AMPKβ-IR;24B-Gal4/+24B-Gal80^ts^ \> rl-IRw^1118^;tub-Gal80^ts^/UAS-rl-IR;24B-Gal4/+24B-Gal80^ts^ \> Dsor1-IRw^1118^;tub-Gal80^ts^/UAS-Dsor1-IR;24B-Gal4/+24B-Gal80 \> hop-IRw^1118^;tub-Gal80^ts^/UAS-hop-IR;24B-Gal4/+hop^tum-L^;24B-Gal80 \> dome^∆^w^1118^ hop^tum-L^;tub-Gal80^ts^/+;24B-Gal4/UAS-dome^∆^24B-Gal80^ts^ \> AKT-IRw^1118^;tub-Gal80^ts^/UAS-AKT-IR;24B-Gal4/+24B-Gal80^ts^ \> AKT-IR;dome^∆^w^1118^;tub-Gal80^ts^/UAS-AKT-IR;24B-Gal4/UAS-dome^∆^MHC-Gal4/+w^1118^;MHC-Gal4,Mhc-RFP/+;MHC-Gal4 \> dome^∆^ (II)w^1118^;MHC-Gal4,MHC-RFP/UAS-dome^∆^;foxo^GFP^;24B-Gal80^ts^/+w^1118^;foxo^GFP^;tub-Gal80^ts^/+;24B-Gal4/+foxo^GFP^;24B-Gal80^ts^ \> dome^∆^w^1118^;foxo^GFP^;tub-Gal80^ts^/+;24B-Gal4/UAS-dome^∆^UAS-dome^∆^/+w^1118^;;UAS-dome^∆^/+UAS-AKT-IR/+w^1118^;UAS-AKT-IR/+;UAS-AKT-IR;dome^∆^/+w^1118^;UAS-AKT-IR/+; UAS-dome^∆^/+Mef2-Gal80^ts^/+w^1118^;tub-Gal80^ts^/+;Mef2-Gal4/+Mef2-Gal80^ts^ \> dome^∆^w^1118^;tub-Gal80^ts^/+;Mef2-Gal4/UAS-dome^∆^srpHemo-3xmCherryw^1118^;; srpHemo-3xmCherry/+crq-Gal4/+w^1118^;;crq-Gal4/+crq-Gal80^ts^ \> rprw^1118^;tub-Gal80^ts^/+;crq-Gal4/UAS-rpr* or *w^1118^;tub-Gal80^ts^/+;crq-Gal4*,*UAS-CD8-mCherry,10xSTAT92E-GFP/UAS-rprcrq-Gal80^ts^/+w^1118^;tub-Gal80^ts^/+;crq-Gal4/+* or *w^1118^;tub-Gal80^ts^/+*;*crq-Gal4,UAS-CD8-mCherry,10xSTAT92E-GFP/+crq-Gal4/+w^1118^;;crq-Gal4,UAS-CD8-mCherry,10xSTAT92E-GFP/+crq-Gal4 \> upd1-IRw^1118^;UAS-upd1-IR/+;crq-Gal4,UAS-CD8-*\
*mCherry,10xSTAT92E-GFP/+crq-Gal4 \> upd3-IRw^1118^;UAS-upd3-IR/+;crq-Gal4,UAS-CD8-mCherry,10xSTAT92E-GFP/+crq-Gal4 \> upd3w^1118^;;crq-Gal4,UAS-CD8-mCherry*,*10xSTAT92E-GFP/UAS-upd3upd2 ^Δ^ upd3^Δ^;crq-Gal80^ts^/+w upd2 ^Δ^ upd3^Δ^;tub-Gal80^ts^/+;crq-Gal4/+upd2 ^Δ^ upd3^Δ^;crq-Gal80^ts^ \> rprw upd2 ^Δ^ upd3^Δ^;tub-Gal80^ts^/+;crq-Gal4/UAS-rprupd2 ^Δ^ upd3^Δ^;upd1-IR/+w upd2 ^Δ^ upd3^Δ^;UAS-upd1-IR/+upd2 ^Δ^ upd3^Δ^;crq-Gal4/+w upd2 ^Δ^ upd3^Δ^;;crq-Gal4/+upd2 ^Δ^ upd3^Δ^;crq-Gal4 \> upd1-IRw upd2 ^Δ^ upd3^Δ^;UAS-upd1-IR/+;crq-Gal4/+MHC^YFP^; srpHemo-3xmCherryw^1118^; MHC^YFP^/+;srpHemo-3xmCherry/+10xSTAT92E-GFP; srpHemo-3xmCherryw^1118^; 10xSTAT92E-GFP/+;srpHemo-3xmCherry/+*

Lifespan/Survival assays {#s4-2}
------------------------

Male flies were collected after eclosion and groups of 20--40 age-matched flies per genotype were placed together in a vial with fly food. All survival experiments were performed at 29°C. Dead flies were counted daily. Vials were kept on their sides to minimize the possibility of death from flies becoming stuck to the food, and flies were moved to fresh food twice per week. Flies were transferred into new vials without CO~2~ anaesthesia.

Negative geotaxis assay/Climbing Assay {#s4-3}
--------------------------------------

Male flies were collected after eclosion and housed for 14 days in age-matched groups of around 20. The assay was performed in the morning, when flies were most active. Flies were transferred without CO~2~ into a fresh empty vial without any food and closed with the open end of another empty vial. Flies were placed under a direct light source and allowed to adapt to the environment for 20 min. Negative geotaxis reflex was induced by tapping the flies to the bottom of the tube and allowing them to climb up for 8 s. After 8 s the vial was photographed. This test was repeated 3 times per vial with 1 min breaks in between. The height each individual fly had climbed was measured in Image J, and the average between all three runs per vial was calculated.

Feeding assays {#s4-4}
--------------

Male flies were aged for 7 days and changed on food supplemented with 0.1% bromophenol blue and 0.5% xylene cyanol. Control flies for each genotype were maintained on non-blue food for background subtraction. Flies were left on the blue or non-blue food for 4 hr at 29°C. After 4 hr flies were anaesthetized with CO~2~ and decapitated to avoid interference of the eye pigment with the measured absorbance. five flies were homogenized in 100 µl PBS per sample. The fly torsos were homogenized and centrifuged for 20 min at 12.000 rpm. The supernatant was collected and absorbance at 620 nm was analysed with a plate reader.

Staining of thorax samples {#s4-5}
--------------------------

For immunofluorescent staining of thorax muscles, we anaesthetized flies and removed the head, wings and abdomen from the thorax. Thorax samples were pre-fixed for 1 hr in 4% PFA rotating at room temperature. Thoraces were then halved sagitally with a razor blade and fixed for another 30 min rotating at room temperature. Samples were washed with PBS + 0.1% Triton X-100, then blocked for 1 hr in 3% bovine serum albumin (BSA) in PBS + 0.1% Triton X-100.

For Lipid-Tox staining, samples were washed with PBS and stained for 2 hr at room temperature with HCS Lipid Tox Deep Red (Thermo Fisher \#H34477; 1:200). For Phalloidin labelling, the samples were washed in PBS after fixation and stained for 2 hr at room temperature with Alexa Fluor 488 Phalloidin (Thermo Fisher \#A12379, 1:20). Afterwards the samples were washed once with PBS and mounted in Fluoromount-G. All mounted samples were sealed with clear nail polish and stored at 4°C until imaging.

Confocal microscopy {#s4-6}
-------------------

Imaging was performed in the Facility for Imaging by Light Microscopy (FILM) at Imperial College London and in the Institute of Neuropathology in Freiburg. A Leica SP5 and SP8 microscope (Leica) were used for imaging, using either the 10x/NA0.4 objective, or the 20x/NA0.5 objective. Images were acquired with a resolution of either 1024 × 1024 or 512 × 512, at a scan speed of 400 Hz. Averages from 3 to 4 line scans were used, sequential scanning was employed where necessary and tile scanning was used in order to image whole flies. For imaging of whole live flies, the flies were anaesthetized with CO~2~ and glued to a coverslip. Flies were kept on ice until imaging. For measuring mean fluorescence intensity, a z-stack of the muscle was performed and the stack was projected in an average intensity projection. Next the area of the muscle tissue analyzed was defined and the mean fluorescent intensity within this area was measured. Images were processed and analysed using Image J.

RNA isolation and reverse transcription {#s4-7}
---------------------------------------

For RNA extraction three whole flies or three thoraces were used per sample. After anaesthetisation, the flies were smashed in 100 µl TRIzol (Invitrogen), followed by a chloroform extraction and isopropanol precipitation. The RNA pellet was cleaned with 70% ethanol and finally solubilized in water. After DNase treatment, cDNA synthesis was carried out using the First Strand cDNA Synthesis Kit (Thermo Scientific) and priming with random hexamers (Thermo Scientific). cDNA samples were further diluted and stored at −20° C until analysis.

Quantitative Real-time PCR {#s4-8}
--------------------------

Quantitative Real-time PCR was performed with Sensimix SYBR Green no-ROX (Bioline) on a Corbett Rotor-Gene 6000 (Corbett). The cycling conditions used throughout the study were as follows: Hold 95°C for 10 min, then 45 cycles of 95°C for 15 s, 59°C for 30 s, 72°C for 30 s, followed by a melting curve. All calculated gene expression values were measured in arbitrary units (au) according to diluted cDNA standards run in each run and for each gene measured. All gene expression values are further normalized to the value of the loading control gene, Rpl1, prior to further analysis.

The following primer sequences have been used in this study:

Gene nameForwardReverse*Akt1*5'-ctttgcgagtattaactggacaga-3'5'-ggatgtcacctgaggcttg-3'*Ilp2*5'-atcccgtgattccaccacaag-3'5'-gcggttccgatatcgagtta-3'*Ilp3*5'-caacgcaatgaccaagagaa-3'5'-tgagcatctgaaccgaact-3'*Ilp4*5'-gagcctgattagactgggactg-3'5'-tggaccggctgcagtaac-3'*Ilp5*5'-gccttgatggacatgctga-3'5'-agctatccaaatccgcca-3'*Ilp6*5'-cccttggcgatgtatttcc-3'5'-cacaaatcggttacgttctgc-3'*Ilp7*5'-cacaccgaggagggtctc-3'5'-caatatagctggcggacca-3'*dome*5'-cggactttcggtactccatc-3'5'-accttgatgaggccaggat-3'*upd1*5'-gcacactgatttcgatacgg-3'5'- ctgccgtggtgctgtttt −3'*upd2*5'-cggaacatcacgatgagcgaat-3'5'-tcggcaggaacttgtactcg-3'*upd3*5'-actgggagaacacctgcaat-3'5'-gcccgtttggttctgtagat-3'*Pepck1*5'-ggataaggtggacgtgaag-3'5'-acctcctgcgaccagaact-3'*Thor*5'-caggaaggttgtcatctcgga-3'5'-ggagtggtggagtagagggtt-3'*InR*5\'-gcaccattataaccggaacc-3\'5\'-ttaattcatccatgacgtgagc-3\'*Akh*5'- agccgtgctcttcatgct-3'5'-aaaggttccaggaccagctc-3'*Hsl*5'-cttggaaatacttgaggggttg-3'5'-agatttgatgcagttctttgagc-3'*bmm*5'-gtctcctctgcgatttgccat-3'5'-ctgaagggacccagggagta-3'*plin1*5'-gcgttctatggtagccttcag-3'5'-gcgtccggatagaaagctg-3'*plin2*5'-gcagaatggcaagagttctga-3'5'-actgtgtgtaggactggatcctc-3'*Rpl1*5'-tccaccttgaagaagggcta-3'5'-ttgcggatctcctcagactt-3'

Smurf assay {#s4-9}
-----------

Smurf assays with blue-coloured fly food were performed to analyse gut integrity in different genotypes. Normal fly food, as described above, was supplemented with 0.1% Brilliant Blue FCF (Sigma Aldrich). Experimental flies were placed on the blue-coloured fly food at 9AM and kept on the food for 2 hr at 29°C. After 2 hr, the distribution of the dye within the fly was analysed for each individual. Flies without any blue dye were excluded, flies with a blue gut or crop were identified as 'non-smurf' and flies which turned completely blue or showed distribution of blue dye outside the gut were classified as 'smurf'.

Western blot {#s4-10}
------------

Dissected legs or thoraces from three flies were used per sample and smashed in 75 µl 2x Laemmli loading buffer (100 mM Tris \[pH 6.8\], 20% glycerol, 4% SDS, 0.2 M DTT). Samples were stored at −80°C until analysis. 7.5 µl of this lysate were loaded per lane. Blue pre-stained protein standard (11--190 kDa) (New England Biolabs) was used. Protein was transferred to nitrocellulose membrane (GE Healthcare). Membrane was blocked in 5% milk in TBST (TBS + 0.1% Tween-20). The following primary antibodies were used: anti-phospho(Ser505)-AKT (Cell Signal Technology (CST) 4054, 1:1,000), anti-AKT (CST 4691, 1:1,000), anti-phospho(Thr172)-AMPKα (CST 2535, 1:1,000), anti-phospho(Thr389)-p70 S6 kinase (CST 9206, 1:1,000), anti-GFP (CST 2956, 1:1,000), anti-phospho-p44/42 MAPK (Erk1/2) (CST 4370, 1:1,000) and anti-α-tubulin (clone 12G10, Developmental Studies Hybridoma Bank, used as an unpurified supernatant at 1:3,000; used as a loading control for all blots). Primary antibodies were diluted in TBST containing 5% BSA and incubated over night at 4°C. Secondary antibodies were HRP anti-rabbit IgG (CST 7074, 1:5,000) and HRP anti-mouse IgG (CST 7076, 1:5,000). Proteins were detected with Supersignal West Pico Chemiluminescent Substrate (Thermo Scientific) or Supersignal West Femto Chemiluminescent Substrate (Thermo Scientific) using a LAS-3000 Imager (Fujifilm). Bands were quantified by densitometry using Image J. Quantifications reflect all experiments performed; representative blots from single experiments are shown.

Thin Layer Chromatography (TLC) for Triglycerides {#s4-11}
-------------------------------------------------

Groups of 10 flies were used per sample. After CO~2~ anaesthesia the flies were placed in 100 µl of ice-cold chloroform:methanol (3:1). Samples were centrifuged for 3 min at 13,000 rpm at 4°C, and then flies were smashed with pestles followed by another centrifugation step. A set of standards were prepared using lard (Sainsbury's) in chloroform:methanol (3:1) for quantification. Samples and standards were loaded onto a silica gel glass plate (Millipore), and a solvent mix of hexane:ethyl ether (4:1) was prepared as mobile phase. Once the solvent front reached the top of the plate, the plate was dried and stained with an oxidising staining reagent containing ceric ammonium heptamolybdate (CAM) (Sigma Aldrich). For visualization of the oxidised bands, plates were baked at 80°C for 20 min. Baked plates were imaged with a scanner and triglyceride bands were quantified by densitometry according to the measured standards using Image J.

Measurement of glucose, Trehalose and Glycogen {#s4-12}
----------------------------------------------

5--7-day-old male flies, kept at 29°C, were used for the analysis. Flies were starved for 1 hr on 1% agar supplemented with 2% phosphate buffered saline (PBS) at 29°C before being manually smashed in 75 μl TE + 0.1% Triton X-100 (Sigma Aldrich). three flies per sample were used. All samples were incubated at 75°C for 20 min and stored at −80°C. Samples were thawed prior to measurement and incubated at 65°C for 5 min to inactivate fly enzymes. A total of 10 μl per sample was loaded for different measurements into flat-bottom 96-well tissue culture plates. Each fly sample was measured four times, first diluted in water for calculation of background fly absorbance, second with glucose reagent (Sentinel Diagnostics) for the measurement of free glucose, third with glucose reagent plus trehalase (Sigma Aldrich) for trehalose measurement, and fourth with glucose reagent plus amyloglucosidase (Sigma Aldrich) for glycogen measurement. Plates were then incubated at 37°C for 1 hr before reading with a microplate reader (biochrom) at 492 nm. Quantities of glucose, trehalose and glycogen were calculated according to measured standards.

Respirometry {#s4-13}
------------

Respiration in flies was measured using a stop-flow gas-exchange system (Q-Box RP1LP Low Range Respirometer, Qubit Systems, Ontario, Canada, K7M 3L5). Ten flies from each genotype were put into an airtight glass tube and supplied with our standard fly food via a modified pipette tip. Each tube was provided with CO~2~-free air while the 'spent' air was concurrently flushed through the system and analysed for its CO~2~ and O~2~ content. All vials with flies were normalized to a control vial with food but no flies inside. In this way, evolved CO~2~ per chamber and consumed O~2~ per chamber were measured for each tube every \~44 min (the time required to go through each of the vials in sequence).

Flow cytometry {#s4-14}
--------------

For flow cytometric analysis of plasmatocytes, 90 flies per sample per genotype were anaesthetized and mechanically dissociated through a 100 µm mesh with 2 mM EDTA in PBS (FACS buffer). The cell suspension is spun down and the resulting cell pellet was resuspended in 5 ml FACS buffer and again rinsed through a 100 µm mesh in a new tube. This washing step was repeated twice. Afterwards the cells were resuspended in 500 µl 2 mM EDTA and Fixable Viability Dye 780 (ebioscience \#65-0865-18, 1:1000). Samples were acquired on a FACS Canto II (BD Biosciences) and analyzed with FlowJo analysis software.

Statistical analysis and handling of data {#s4-15}
-----------------------------------------

For real-time quantitative PCR, TLCs, MFI quantification, western blot quantifications and colorimetric measurements for glucose, trehalose and glycogen levels an unpaired t-test or one-way ANOVA was used to calculate statistical significance, as noted in the figure legends. Respirometer data was analysed with a Mann-Whitney test. Lifespan/Survival assays, where analysed with the Log-Rank and Wilcoxon test. Stars indicate statistical significance as followed: \*p\<0.05, \*\*p\<0.01 and \*\*\*p\<0.001. All statistical tests were performed with Excel or GraphPad Prism software.

All replicates are biological. No outliers were omitted, and all replicates are included in quantitations (including in cases where a single representative experiment is shown). Flies were allocated into experimental groups according to their genotypes. Masking was not used. For survival experiments, typically, the 50% of flies that eclosed first from a given cross were used for an experiment. For smaller-scale experiments, flies were selected randomly from those of a given age and genotype.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The influence of metabolism and lifestyle on muscle function is well known and documented. The role of muscle function in lifespan and metabolism is now, increasingly, being teased out. In this study, the authors investigate the JAK/STAT signalling pathway in *Drosophila* muscle and suggest that it is a critical regulator of lifespan and metabolism. Using genetic interventions, the measurement of lifespan and the analysis of behaviour, the authors show that the genes domeless and hopscotch link to AKT activity to affect metabolic regulation, and lifespan. They also suggest that signals from hemocytes play an important role, though the interpretation of this is not straightforward given the metabolic phenotype is not recapitulated by ablating hemocytes. In sum, the authors make a persuasive case for a link between muscle and lifespan, and the system which they use will increasingly valuable for further studies.

**Decision letter after peer review:**

Thank you for submitting your article \"Muscle function and homeostasis require macrophage-derived cytokine inhibition of AKT activity in *Drosophila*\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by K VijayRaghavan as the Senior and Reviewing Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Kierdorf et al. investigate the JAK/STAT signalling pathway in *Drosophila* muscle as a critical regulator of lifespan and metabolism. The authors show some convincing data linking domeless and hopscotch to AKT activity, metabolic misregulation, and shortened life. Additional data suggest that hemocyte Upd1 is the primary signal. This link is less well supported, but the redundancy between Upd1-3 make these experiments difficult to interpret.

The manuscript needs substantial revision and the authors may want to consider reducing (or even dropping?) the metabolism part.

Essential revisions:

There are a some critical questions that need to be addressed.

1\) What is the control line used in these studies? Were all of the fly stocks backcrossed to a parental line? Without backcrossing, the experiments are lacking proper genetic controls. At least for the lifespan studies, the differences observed are easily obtained by heterosis, especially for the lines with multiple transgenic elements. An alternative would have been to use the temperature control, since all studies used a thermogenetic approach, but there appears to be some leakage with the system (Figure 1---figure supplement 1D, although AKT and other metabolic parameters weren\'t measured). The dependency on only thermogenetic manipulations is a minor weakness, but adding a GeneSwitch or other inducible approach would greatly support the findings.

2\) How did the authors determine a single vial of 20 flies would be sufficient to resolve 5% differences in lifespan? And what is a \"lifespan effect size\"? Do they mean a 5% change in median or mean lifespan? For fly studies, we typically see a requirement of \>200 flies to detect 5-10% differences in mean lifespan. Additionally, the various lifespans are described as pooled independent experiments. This doesn\'t seem right. In Figure 1B, that would mean the experimental line was tested three separate times with less than 20 flies per trial. Individual vials within a single trial should not be considered independent replicates. The lifespan studies are mostly believable, but some of the studies would benefit from independent replication. For example, we don\'t concur with the conclusion from Figure 4F. The data there is not sufficient to claim a further reduction in longevity with upd2/3 knockouts in a plasmocyte-deleted line.

3\) The magnitude of change in AKT levels sometimes seem inconsistent with the effects on lifespan (e.g., comparing Figures 1---figure supplement 1J-K, 1F-H, and Figure 2---figure supplement 1B-C).

4\) It is arguable that the metabolic phenotype is due to the haemocyte activity, since it cannot be recapitulated by their ablation.

The authors claim that the phenotype observed upon muscle specific dome inhibition is not due to gut malfunction. They support this claim by assessing gut integrity through the \"smurf\" assay. However, gut integrity is not equivalent to gut functionality. To properly exclude the gut, the authors should consider crucial gut functions impacting metabolic homeostasis such as feeding, digestion, nutrient absorption or gut contractility. These aspects should be at least discussed.

5\) The potential gut contribution to some aspects of the observed phenotype cannot be easily dismissed especially considering its endocrine functions, that can be independent to the gut barrier integrity. In this context, for instance, since dome is expressed by the gut muscular layers, its depletion could potentially trigger upd2 production, which in turn can activate AKH signalling, a known mediator of energy reserve mobilization and positive regulator of basal metabolism.

6\) The authors conclude that haemocytes are the mediators of the UPD-dome-STAT-pAKT-foxo circuit in the muscles, since haemocyte ablation reduces STAT-GFP reporter activity. There are two problems here:

Firstly, the extent to which haemocyte ablation is achieved using the experimental conditions is unclear. Can the authors be sure they have removed all hemocytes? Secondly, despite the effects on STAT, hemocyte ablation has no effect on the metabolic phenotype, which implies the presence of an independent, unexplored mediator of dome activation (despite the title of the article which suggests hemocytes as the sole effector of muscle function and homeostasis).

7\) The involvement of hemocytes is sustained only by the evidence of stat activation. In this context, a reduced lifespan, alone or in combination with UPDs mutants/IRs is not particularly informative, since it may just reflect the effect of immunosuppression, rather than be related to muscle function and homeostasis. It would be more informative, for example, to assess the effects on climbing activity.

8\) While hemocyte ablation, or UPD suppression, reduces STAT-GFP readout, no information is provided on the effect on AKT, which appears to mostly recapitulate the different aspects of muscle dome suppression. If hemocytes are responsible for dome activation, their ablation would phenocopy dome^Δ^ induced upregulation of pAKT in muscles.

If the proposed model is correct, the pAKT upregulation should be rescued by foxo-GFP expression.

9\) Another crucial point is the origin of UPD ligands. Only targeted knock-down of all UPDs within the hemocyte population can pinpoint a crucial role for this population on the muscle. The authors should see if this is speedily feasible.
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Author response

> Essential revisions:
>
> There are a some critical questions that need to be addressed.
>
> 1\) What is the control line used in these studies? Were all of the fly stocks backcrossed to a parental line? Without backcrossing, the experiments are lacking proper genetic controls. At least for the lifespan studies, the differences observed are easily obtained by heterosis, especially for the lines with multiple transgenic elements. An alternative would have been to use the temperature control, since all studies used a thermogenetic approach, but there appears to be some leakage with the system (Figure 1---figure supplement 1D, although AKT and other metabolic parameters weren\'t measured). The dependency on only thermogenetic manipulations is a minor weakness, but adding a GeneSwitch or other inducible approach would greatly support the findings.

We apologise that the genetic backgrounds were not completely clear. We have revised the Materials and methods to clarify this---essentially, all lines were backcrossed onto our isogenic *w1118* control line, except for lines already on another isogenic background that could then be independently compared, and all crosses were performed with driver females so that all the (male) experimental progeny flies would have a uniform X chromosome. This should eliminate the concern regarding heterosis. We agree that a nonthermogenetic system would be desirable as an adjunct to the *Gal80^ts^*approach we have used, but our experience with the GeneSwitch system has been so negative (off-target effects of RU486, weak expression when the system works) that we now avoid its use. However, the manuscript does include non-thermogenetic approaches as well---for example, the Mhc-Gal4 experiments shown in S1.

> 2\) How did the authors determine a single vial of 20 flies would be sufficient to resolve 5% differences in lifespan? And what is a \"lifespan effect size\"? Do they mean a 5% change in median or mean lifespan? For fly studies, we typically see a requirement of \>200 flies to detect 5-10% differences in mean lifespan. Additionally, the various lifespans are described as pooled independent experiments. This doesn\'t seem right. In Figure 1B, that would mean the experimental line was tested three separate times with less than 20 flies per trial. Individual vials within a single trial should not be considered independent replicates. The lifespan studies are mostly believable, but some of the studies would benefit from independent replication. For example, we don\'t concur with the conclusion from Figure 4F. The data there is not sufficient to claim a further reduction in longevity with upd2/3 knockouts in a plasmocyte-deleted line.

The comment regarding experimental power is correct---our calculation was wrong because of underestimation of the variance of survival time. (Most of our experience in this regard is with animals dying of bacterial infection, which can show much lower survival variance.) The incorrect statement has been removed. We are fortunate that the survival effect we actually observe in these experiments is generally 25% or more, so that our cohort sizes are large enough for robust conclusions to be drawn. With regard to pooling independent survivals, this statement was in error, due to confusion among the authors regarding the nature of an experimental cohort. With regard to the specific experiment shown in Figure 4F, we have changed our discussion of the result to reflect the fact that we cannot tell whether longevity is further reduced.

> 3\) The magnitude of change in AKT levels sometimes seem inconsistent with the effects on lifespan (e.g., comparing Figures 1---figure supplement 1J-K, 1F-H, and Figure 2---figure supplement 1B-C).

It's true that the effects we see on lifespan do not map in any obvious, linear way onto the effect on AKT levels (although, in general, manipulations that give smaller effects on AKT tend to give smaller effects on lifespan---the only real exception to this is *Mef2-Gal80^ts^*, which gives a smaller effect on lifespan than would be expected from its effect on AKT abundance). We don't know why, exactly, beyond the (trivial) observation that dome-AKT signaling is not the only regulator of lifespan. However, our epistasis experiments show clearly that the effect on AKT is an important mediator of the effect of dome inhibition---this is the central point of our work.

> 4\) It is arguable that the metabolic phenotype is due to the haemocyte activity, since it cannot be recapitulated by their ablation.
>
> The authors claim that the phenotype observed upon muscle specific dome inhibition is not due to gut malfunction. They support this claim by assessing gut integrity through the \"smurf\" assay. However, gut integrity is not equivalent to gut functionality. To properly exclude the gut, the authors should consider crucial gut functions impacting metabolic homeostasis such as feeding, digestion, nutrient absorption or gut contractility. These aspects should be at least discussed.

We now discuss these points in the Discussion. We also now provide feeding data for *24BGal80^ts^\> dome^Δ^*animals, showing that they consume the same amount of food as the control genotype (Figure 1---figure supplement 1S).

> 5\) The potential gut contribution to some aspects of the observed phenotype cannot be easily dismissed especially considering its endocrine functions, that can be independent to the gut barrier integrity. In this context, for instance, since dome is expressed by the gut muscular layers, its depletion could potentially trigger upd2 production, which in turn can activate AKH signalling, a known mediator of energy reserve mobilization and positive regulator of basal metabolism.

The reviewer is correct about the role of AKH signaling as a known mediator of energy mobilization. We have tested the specific scenario described (upd2 \> AKH) by assaying expression of AKH and known and suspected AKH target genes in *24B-Gal80^ts^\>dome^Δ^*animals; these data are included as Figure 3---figure supplement 1I-M. In general, though these data are consistent with there being some change in AKH signaling, they do not suggest a strong effect. In a more general sense, we do now discuss other potential contributions of the gut.

> 6\) The authors conclude that haemocytes are the mediators of the UPD-dome-STAT-pAKT-foxo circuit in the muscles, since haemocyte ablation reduces STAT-GFP reporter activity. There are two problems here:
>
> Firstly, the extent to which haemocyte ablation is achieved using the experimental conditions is unclear. Can the authors be sure they have removed all hemocytes? Secondly, despite the effects on STAT, hemocyte ablation has no effect on the metabolic phenotype, which implies the presence of an independent, unexplored mediator of dome activation (despite the title of the article which suggests hemocytes as the sole effector of muscle function and homeostasis).

We have now included experimental validation of the plasmatocyte ablation by imaging and flow cytometry (Figure 4---figure supplement 1A, B); we see that almost all (\>95%) of plasmatocytes are eliminated. We agree with the reviewer regarding the role of plasmatocytes: we have changed the title to avoid confusion. In the main text we clearly state that plasmatocytes are one relevant source of signal, but they are probably not the only source in wild-type animals (and are certainly not the only source in plasmatocyte-ablated or *upd1*-knockdown animals).

> 7\) The involvement of hemocytes is sustained only by the evidence of stat activation. In this context, a reduced lifespan, alone or in combination with UPDs mutants/IRs is not particularly informative, since it may just reflect the effect of immunosuppression, rather than be related to muscle function and homeostasis. It would be more informative, for example, to assess the effects on climbing activity.

We have assayed climbing activity in plasmatocyte-ablated flies. We found a clear reduction in their climbing activity after hemocyte ablation compared to the control genotype, in line with our findings that hemocyte ablation further results with the appearance of lipid inclusions in muscle of these animals. These data are now included as Figure 4---figure supplement 1C.

> 8\) While hemocyte ablation, or UPD suppression, reduces STAT-GFP readout, no information is provided on the effect on AKT, which appears to mostly recapitulate the different aspects of muscle dome suppression. If hemocytes are responsible for dome activation, their ablation would phenocopy dome^Δ^ induced upregulation of pAKT in muscles.
>
> If the proposed model is correct, the pAKT upregulation should be rescued by foxo-GFP expression.

Due to limitations in time we were not able to combine plasmatocyte ablation with the *foxo-GFP* construct. The reviewer is absolutely right that *foxo-GFP* should rescue the high abundance of pAKT; this is shown as Figure 3---figure supplement 1D.

> 9\) Another crucial point is the origin of UPD ligands. Only targeted knock-down of all UPDs within the hemocyte population can pinpoint a crucial role for this population on the muscle. The authors should see if this is speedily feasible.

We agree that this would be desirable, but we have been unable to combine all the required knockdowns in a single fly in the time available to us.
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